Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine adjuvanted with MPLA liposomes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine adjuvanted with MPLA liposomes, covering 2024-07-10 to 2024-07-10. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults [Phase 1]